Half Moon Bay, California
United States
60
2025-10-02
The entities that hold a legal rights for patent applications filed by inventor Berner Bret:
Bret Berner from Half Moon Bay, US has applied for patents for these inventions. The list has both pending applications and granted patents:
CRYSTALLINE 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID
#2 | 2023-12-14CRYSTALLINE 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID
#3 | 2022-09-22Formulations of 4-Methyl-5-(Pyrazin-2-yl)-3H-1,2-Dithiole-3-Thione, Taste-Modified Formulations, and Methods of Making and Using Same
#4 | 2022-06-02Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid
#5 | 2020-03-26Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
#6 | 2019-07-11Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-l,2-dithiole-3-thione, taste-modified formulations, and methods of making and using same
#7 | 2019-07-11Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione, and methods of making and using same
#8 | 2019-06-13Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid
#9 | 2019-06-13Naloxone Transdermal Delivery Devices and Methods for Using the Same
#10 | 2019-05-23Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
#11 | 2018-10-11Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
#12 | 2018-07-12COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY
#13 | 2018-01-18SITE SPECIFIC DOSING OF A BTK INHIBITOR
#14 | 2017-06-22SHELL-AND-CORE DOSAGE FORM APPROACHING ZERO-ORDER DRUG RELEASE
#15 | 2016-09-15METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE FORM
#16 | 2016-08-18Formulation for oral administration of proteins
#17 | 2016-06-30Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
#18 | 2016-02-18FORMULATIONS CONTAINING REVERSIBLE COVALENT COMPOUNDS
#19 | 2016-02-11PULSATILE GASTRIC RETENTIVE DOSAGE FORMS
#20 | 2015-12-10Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance
#21 | 2015-07-02Formulation for Oral Administration of Proteins
#22 | 2015-07-02Shell-and-core dosage form approaching zero-order drug release
#23 | 2015-06-18Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
#24 | 2015-06-11METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE FORM
#25 | 2015-04-16Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
#26 | 2015-04-09Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions
#27 | 2015-04-09Methods and Compositions for Treating Withdrawal Syndromes Using Non-Sedative Dexmedetomidine Transdermal Compositions
#28 | 2015-04-09Methods and Compositions for Managing Pain Comprising Dexmedetomidine Transdermal Compositions
#29 | 2015-04-09Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
#30 | 2015-04-09Dexmedetomidine transdermal delivery devices and methods for using the same
#31 | 2014-05-15GASTRIC RETENTIVE GABAPENTIN DOSAGE FORMS AND METHODS FOR USING SAME
#32 | 2014-03-13GASTRIC RETAINED GABAPENTIN DOSAGE FORM
#33 | 2013-11-28COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL MOTILITY DYSFUNCTION
#34 | 2013-11-14Methods of treatment using a gastric retained gabapentin dosage form
#35 | 2013-08-29Gastric retained gabapentin dosage form
#36 | 2013-06-27Shell-and-core dosage form approaching zero-order drug release
#37 | 2013-06-20METHODS FOR TREATING VASOMOTOR SYMPTOMS USING GABA ANALOGS IN A GASTRIC RETENTIVE DOSAGE FORM
#38 | 2013-06-13GASTRIC RETENTIVE ORAL DOSAGE FORM WITH RESTRICTED DRUG RELEASE IN THE LOWER GASTROINTESTINAL TRACT
#39 | 2013-05-09Gastric retentive gabapentin dosage forms and methods for using same
#40 | 2012-11-15Gastric retained gabapentin dosage form
#41 | 2012-11-08Gastric retained gabapentin dosage form
#42 | 2012-06-14Gastric retained gabapentin dosage form
#43 | 2012-05-24Methods of treatment using a gastric retained gabapentin dosage
#44 | 2012-03-29Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
#45 | 2012-03-15Methods of treatment using a gastric retained gabapentin dosage
#46 | 2012-03-15Gastric retained gabapentin dosage form
#47 | 2012-02-02Methods of treatment using a gastric retained gabapentin dosage
#48 | 2011-12-08Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
#49 | 2011-10-20Gastric retained gabapentin dosage form
#50 | 2011-09-29Shell and core dosage form approaching zero-order drug release
#51 | 2011-09-29Dosage forms that facilitate rapid activation of barley protease zymogen
#52 | 2011-09-08METHODS OF TREATING NON-NOCICEPTIVE PAIN STATES WITH GASTRIC RETENTIVE GABAPENTIN
#53 | 2011-07-12Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
#54 | 2010-02-11Methods of treatment using a gastric retained gabapentin dosage
#55 | 2009-08-20Methods for treating vasomotor symptoms using GABA analogs in a gastric retentive dosage form
#56 | 2009-07-09GASTRIC RETENTIVE GABAPENTIN DOSAGE FORMS AND METHODS FOR USING SAME
#57 | 2009-01-29Pulsatile gastric retentive dosage forms
#58 | 2007-08-09Gastric retentive gabapentin dosage forms and methods for using same
#59 | 2006-07-20Methods of treating non-nociceptive pain states with gastric retentive gabapentin
#60 | 2005-03-24Methods of treatment using a gastric retained gabapentin dosage
236487 ⎘